A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
← catalyst calendarNCT06709014 · readout ≤ 499 d
Sponsored by Annovis Bio Inc. (industry) · ANVS — their whole pipeline →. With Prevail Infoworks, ProPharma Group.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
760estimated
Sites
78
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-04 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Early Alzheimers Disease
Interventions
- Drug: buntanetap/posiphen
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFAlzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
measured From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
measured From screening to 6-month readout, to end of treatment at 18 months.
Permalink · ANVS's whole pipeline · Catalyst calendar · Every registered study · What changed